Lantern Pharma (NASDAQ: LTRN), an AI company developing targeted cancer therapies using its proprietary RADR® AI and machine learning platform, will present at the ThinkEquity Conference on Oct. 15, 2026, at 3:30 p.m. ET at the Mandarin Oriental in New York City. The event, a key gathering for growth-oriented investors, provides a platform for Lantern to showcase its progress and vision. A live webcast will be available, and management will hold one-on-one investor meetings throughout the conference.
The presentation matters because it offers investors a direct update on Lantern's pipeline, which includes LP-184 (zirdafulven), LP-300, and LP-284, along with its CNS-focused subsidiary, Starlight Therapeutics, and AI subsidiary, Open-Medicine AI. The company's RADR platform integrates large-scale genomic and biological data with machine learning to identify patients most likely to benefit from its therapies, aiming to transform the cost, pace, and precision of oncology drug development. By guiding biomarker-driven clinical development, RADR could reduce the high failure rates and costs associated with traditional drug development, making Lantern a potential standout in the competitive biopharma sector.
For investors, the ThinkEquity Conference is a chance to assess Lantern's strategy and data in person. The live webcast and one-on-one meetings facilitate direct engagement, which is vital for a clinical-stage company where milestones drive valuation. As AI continues to disrupt drug development, Lantern's ability to execute on its RADR-driven approach could position it as a leader in precision oncology, especially if its pipeline candidates demonstrate promising results.
For those unable to attend, the full press release is available at https://ibn.fm/hmTGq. Additional news and updates can be found in the company's newsroom at https://ibn.fm/LTRN. The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication, including editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers, among other corporate communications solutions. The full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
